


**New  
Date**  
Sept 22,  
2018



**Houston Marriott  
West Loop By the Galleria**  
1750 West Loop South  
Houston, TX 77027  
Phone: (713) 960-0111

Jointly provided by:



**Saturday  
September 22, 2018  
7:00 AM - 3:30 PM**

**Emerging Strategies in Novel Targeted  
Therapies for Genitourinary Cancers  
(Prostate Cancer, Renal Cell Carcinoma and  
Urothelial Bladder Carcinoma)**

**Program Director: Eric Jonasch, MD**  
Professor, Department of Genitourinary Medical Oncology, Division of Cancer  
Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

**Educational Grants:** Ferring Pharmaceuticals Inc.; Eisai, Inc.

For online registration and more information visit: [www.cancernetus.com](http://www.cancernetus.com)

**REGISTRATION FORM**

**Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers  
(Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)**

First Name \_\_\_\_\_ Middle Initial \_\_\_\_\_ Last Name \_\_\_\_\_

Physician  Pa-C  NP  PhD  Pharmacist  Industry  Nurse  Other

Mailing Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email \_\_\_\_\_

Specialty \_\_\_\_\_

**Registration Fee** (Registration fee includes buffet breakfast, lunch and syllabus book.)

	Early Registration Fee - Up to 9/12/18	Discounted Registration Fee - 9/13/18 - 9/15/18	Regular Registration Fee - 9/16/18 - 9/22/18
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Nurses, Nurse Practitioners, Physician Assistants	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Pharmacists, Fellows	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Industry †	\$350.00	\$400.00	\$450.00

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

**No refund; substitution is allowed.**

Payment may be made:  MC  Visa  Discover  Check

Credit Card Number \_\_\_\_\_ Expiration Date \_\_\_\_\_

Name and address (as given on the monthly credit card statement) \_\_\_\_\_

Pharmacist e-profile NABP#: \_\_\_\_\_ Pharmacist DOB (MMDD): \_\_\_\_\_

Signature \_\_\_\_\_

Register online at [www.cancernetus.com](http://www.cancernetus.com)  
Please make checks payable to **CancerNet**. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: [brianw@cancernetus.com](mailto:brianw@cancernetus.com)

Fax registration to: 443-267-0016  
Mail registration to:  
860 Hebron Pkwy, Suite 1104  
Lewisville, TX 75057  
 Check box to receive information  
about Live and Webcast programs.  
You can unsubscribe at any time.

## Faculty

### **Hans Hammers, MD, PhD**

Associate Professor, Department of Internal Medicine, The UT Southwestern Medical Center, Dallas, TX

### **Eric Jonasch, MD**

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Ashish M. Kamat, MD**

Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Seth Lerner, MD**

Professor, Scott Department of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Baylor College of Medicine Medical Center, Houston, TX

### **Sumit K Subudhi, MD, PhD**

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Nizar M. Tannir, MD**

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Amado J. Zurita-Saavedra, MD**

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)**

**Saturday, September 22, 2018**

**Houston Marriott West Loop By the Galleria**

1750 West Loop South, Houston, TX 77027

Phone: (713) 960-0111

### **Statement of Need / Program Overview**

This symposium is intended to improve care of patients with prostate cancer, renal cell carcinoma and urothelial bladder carcinoma by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

### **Target Audience**

This symposium is directed primarily to hematologists/oncologists, urologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in genitourinary cancers such as prostate cancer, renal cell carcinoma and urothelial bladder carcinoma. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

### **Learning Objectives**

- Appraise the current role of systemic therapy in nonmetastatic prostate carcinoma (PC)
- Select novel therapies for newly diagnosed metastatic PC
- Evaluate the role of immunotherapy options with check point inhibitors in PC
- Apply multitargeted kinase inhibitor, lenvatinib in the treatment of metastatic renal cell carcinoma (RCC)
- Examine optimal therapy with MET, AXL and VEGF receptor Inhibitor, canozantinib in the treatment of metastatic RCC
- Assess the immunotherapy options with novel PD-1/PD-L1 checkpoint inhibitors and targeted therapy combinations in patients with RCC
- Review the genetic alterations in the molecular subtypes of urothelial bladder cancer (UBC)
- Appraise the efficacy and safety of novel immunotherapy approaches with PD-1/PD-L1 antibodies in patients with UBC

## Agenda

# Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)

7:00 AM	Registration and Breakfast Buffet	
8:25 AM	Welcome and Introductions	<i>Eric Jonasch, MD</i>
<b>PROSTATE CANCER</b>		
8:30 AM	Pretest (Case Vignettes - ARS)	<i>Eric Jonasch, MD / Amado Zurita, MD / Sumit Subudhi, MD, PhD</i>
8:45 AM	The Current Role of Systemic Therapy in Nonmetastatic Prostate Carcinoma	<i>Eric Jonasch, MD</i>
9:15 AM	Newly Diagnosed Metastatic Prostate Carcinoma: Has The Paradigm Changed?	<i>Amado Zurita, MD</i>
9:45 AM	Immunotherapy in Prostate Cancer: Promises and Pitfalls	<i>Sumit Subudhi, MD, PhD</i>
10:15 AM	Posttest (Case Vignettes - ARS)	<i>Eric Jonasch, MD / Amado Zurita, MD / Sumit Subudhi, MD, PhD</i>
10:30 AM	<b>BREAK</b>	
<b>RENAL CELL CARCINOMA</b>		
10:45 AM	Pretest (Case Vignettes - ARS)	<i>Hans Hammers, MD, PhD / Eric Jonasch, MD / Nizar M. Tannir, MD</i>
11:00 AM	Advances in Multitargeted Kinase Inhibitor in the Treatment of Metastatic Renal Cell Carcinoma (RCC): Lenvatinib	<i>Hans Hammers, MD</i>
11:30 AM	Update on MET, AXL and VEGF Receptor Inhibitor in the Treatment of Metastatic RCC: Cabozantinib	<i>Eric Jonasch, MD</i>
12:00 PM	<b>LUNCH</b>	
1:00 PM	Immunotherapy with Novel PD-1 Checkpoint Inhibitors and Targeted Therapy Combinations in the Treatment of RCC	<i>Nizar M. Tannir, MD</i>
1:30 PM	Posttest (Case Vignettes - ARS)	<i>Hans Hammers, MD, PhD / Eric Jonasch, MD / Nizar M. Tannir, MD</i>
<b>UROTHELIAL BLADDER CARCINOMA</b>		
1:45 PM	Pretest (Case Vignettes - ARS)	<i>Seth Lerner, MD / Ashish M. Kamat, MD</i>
2:00 PM	Genetic Alterations in the Molecular Subtypes of Urothelial Bladder Cancer	<i>Seth Lerner, MD</i>
2:30 PM	<b>BREAK</b>	
2:45 PM	Update on Immunotherapy with PD-1/PD-L1 Antibodies in Patients with UBC	<i>Ashish M. Kamat, MD</i>
3:15 PM	Posttest (Case Vignettes - ARS)	<i>Seth Lerner, MD / Ashish M. Kamat, MD</i>
3:30 PM	Closing Comments and Adjourn	<i>Eric Jonasch, MD</i>

## Physicians / Nurses / Pharmacists



JOINT ACCREDITATION  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Credit Designation** - Amedco LLC designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™ for physicians, 5.5 contact hours for nurses and 5.5 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Participants may reserve guest rooms by calling (713) 960-0111



860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057  
Tel: (972) 459-5222 • Fax: (443) 267-0016  
www.cancernetus.com